The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors
Open Access
- 12 August 2002
- journal article
- editorial commentary
- Published by Wiley in Arthritis Care & Research
- Vol. 47 (4), 349-355
- https://doi.org/10.1002/art.10560
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsHeart, 2001
- IndobufenDrugs & Aging, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Overview — mechanisms of action of anti-inflammatory drugsPublished by Springer Nature ,1996
- Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarctionEuropean Heart Journal, 1993
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988
- Randomised trial of prophylactic daily aspirin in British male doctorsBMJ, 1988